Regeneron Pharmaceuticals Inc. – best known for its antibody drug development platform and commercial success with Eylea (aflibercept) – is pivoting increasingly toward oncology. The company has one cancer drug on the market, the PD-1 inhibitor Libtayo (cemiplimab) in partnership with Sanofi, but behind it are a maturing pipeline of bispecific antibodies that Regeneron hopes will catapult the company into a serious oncology player.
Regeneron Wades Deeper Into Oncology With Ambitions To Be A Force In The Space
Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.
More from Anticancer
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.